Physician

Steven L Wallentine, MD

According to 2025 Medicare claims, Steven Wallentine, MD (NPI: 1790736122) practices hematology/oncology in the Provo-Orem-Lehi, UT market, with the plurality of this provider's patient population coming from Utah, UT. This provider's primary affiliated billing organization is REVERE HEALTH PC (NPI: 1093764805; TIN: 870281028) and primary practice location at 84604-3305. Wallentine is affiliated with the Aledade 201 National MSSP (ACO ID: A5522) and Revere Health Collaborative Network, LLC (ACO ID: D0042), participating under both the MSSP and REACH models.

Wallentine's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,292 traditional Medicare patients, billed 195,261 HCPCS/CPT codes, and received $2,973,207 in Medicare payments. The top billing code was 84443 (Blood test, thyroid stimulating hormone (tsh)). Part D data shows 1,574 prescription claims across 213 beneficiaries totaling $4,404,201 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 35 claims. Open Payments data shows 53 records totaling $1,027. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $783,007 to $4,404,201. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,241	156,463	$2,213,859
2016	1,328	231,467	$2,561,533
2017	1,416	290,032	$3,093,175
2018	1,589	215,595	$3,230,032
2019	1,594	222,604	$3,807,278
2020	1,546	243,902	$3,726,082
2021	1,248	170,832	$3,198,083
2022	1,256	192,360	$2,581,838
2023	1,252	187,856	$2,379,401
2024	1,292	195,261	$2,973,207

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	125	647	$783,007
2016	150	891	$1,137,581
2017	147	927	$1,348,888
2018	160	1,011	$1,799,270
2019	194	1,150	$2,832,916
2020	191	1,069	$2,958,922
2021	187	1,050	$2,740,566
2022	199	1,228	$2,671,592
2023	234	1,383	$2,937,245
2024	213	1,574	$4,404,201

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	29	$23,589
2016	N/R	12	$10,547
2017	N/R	101	$27,913
2018	N/R	130	$19,604
2019	N/R	62	$7,828
2020	N/R	108	$9,280
2021	N/R	93	$6,418
2022	N/R	150	$6,128
2023	N/R	94	$9,564
2024	N/R	35	$913

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
84443	Blood test, thyroid stimulating hormone (tsh)	178	237	$16
80053	Blood test, comprehensive group of blood chemicals	499	1,099	$10
96372	Injection of drug or substance under skin or into muscle	237	576	$10
36415	Insertion of needle into vein for collection of blood sample	826	1,444	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	537	1,280	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	57	1,710	$648,594
Lenalidomide	Lenalidomide	51	1,323	$488,258
Pomalyst	Pomalidomide	20	560	$457,055
Imbruvica	Ibrutinib	25	700	$411,867
Revlimid	Lenalidomide	22	609	$402,770

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$631
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	53	$1,027	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Steven L. Wallentine, MD?

Tedicare shows public-source Medicare data for Steven L. Wallentine, MD (NPI 1790736122), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Steven L. Wallentine, MD have ACO affiliation data?

Steven L. Wallentine, MD is shown with ACO affiliation data for Aledade 201 National MSSP (MSSP, ACO ID A5522) and Revere Health Collaborative Network, LLC (REACH, ACO ID D0042).

What billing organization is linked to Steven L. Wallentine, MD?

Steven L. Wallentine, MD is linked to REVERE HEALTH PC (billing NPI 1093764805) in the available physician profile data.

Does Steven L. Wallentine, MD have Open Payments data?

Steven L. Wallentine, MD has 53 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.